Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial Summary: This Phase 1b trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of co-administering once-weekly subcutaneous cagrilintide (at various doses) with semaglutide 2.4 mg in participants for weight management
Figuring out how well the drug worked wasnt as simple as measuring weight loss because the kids are still growing, and each child grows at different rates, Fox said
RehmanATyreeSMFehlbaumSDunn GalvinGPanagosCGGuyBet al
The vial should not be shaken
Read the study and explore how strengthening prepregnancy health can help improve outcomes for women and babies: #WomensHealth #WomensHealthcare #MaternalHealth #PreconceptionHealth #FolicAcid #BirthDefectsPrevention #PregnancyCare #PublicHealth #WHNP #FNP #CNM #NursePractitioner To view or add a comment, sign in GLP-1 Exposure in Early #Pregnancy May Be Less Concerning Than Previously Thought A new analysis suggests that inadvertent exposure to #GLP-1 receptor agonists during early pregnancy is unlikely to significantly increase risks for the developing baby
Denton CP, Khanna D
